Cosentyx (secukinumab) is a monoclonal antibody known as an interleukin 17 (IL-17) inhibitor. It's used to treat several inflammatory conditions, including plaque psoriasis, ankylosing spondylitis, and hidradenitis suppurativa. Cosentyx (secukinumab) comes as a pre-filled pen and syringe, and is typically injected under the skin monthly. It can also be given as an infusion through the veins by a healthcare provider for certain conditions, usually in a clinic setting. Side effects aren't common, but can include the common cold and diarrhea.
Plaque psoriasis (PsO) in people ages 6 years and older
Psoriatic arthritis (PsA) in people ages 2 years and older who weigh at least 33 lbs
Ankylosing spondylitis (AS) in adults
Non-radiographic axial spondyloarthritis (nr-axSpA) in adults
Enthesitis-related arthritis in people ages 4 years and older who weigh at least 33 lbs
Hidradenitis suppurativa in adults
Cosentyx (secukinumab) is a monoclonal antibody that works as an interleukin inhibitor. It blocks a protein in your immune system called interleukin-17 (IL-17), which tends to be overly active in certain inflammatory conditions. In doing so, Cosentyx (secukinumab) lowers swelling, pain, and inflammation.
Source: DailyMed
Side effects that you should report to your care team as soon as possible:
Side effects that usually do not require medical attention (report these to your care team if they continue or are bothersome):
Works well to treat several different inflammatory problems
Injected monthly (after the loading doses)
Available as a prefilled syringe or Sensoready pen for easy at-home injections
Can be used in children (for plaque psoriasis, psoriatic arthritis, and enthesitis-related arthritis)
Only available as injections
Raises the risk of infections
Can worsen inflammatory bowel disease (IBD) (e.g., ulcerative colitis or Crohn's disease) symptoms
Pens and prefilled syringes not appropriate for those with latex allergy
Receiving Cosentyx (secukinumab) can raise your risk for an infection that's difficult to treat. If you get sick, your provider might ask you to stop Cosentyx (secukinumab) until your infection is treated. Let your provider know if you have symptoms such as fever, body aches, chills, and cough.
Live vaccines aren't recommended after you've started Cosentyx (secukinumab). Before you receive any vaccines, let your provider know you're taking Cosentyx (secukinumab) so they can let you know if it's safe for you to get vaccinated.
Don't breastfeed while taking Cosentyx (secukinumab) unless you've discussed the benefits and risks of doing so with your provider. Cosentyx (secukinumab) hasn't been well-studied during breastfeeding, but limited research suggests it's unlikely to cause harm to a nursing baby.
Store Cosentyx (secukinumab) pens or prefilled syringes in the refrigerator in the original carton and protect it from light.
If needed, you can store Cosentyx (secukinumab) pens or prefilled syringes at room temperature for up to 4 days. If you do store it at room temperature, make sure to write down the new 4-day expiration date.
If Cosentyx (secukinumab) pens or prefilled syringes have been sitting at room temperature for less than 4 days, you can put it back in the fridge one time. If you do, the medication can be used up until the manufacturer's expiration date on the package.
Tips for using [Cosentyx (secukinumab) injections under the skin at home:
Cosentyx (secukinumab) is available as a Sensoready Pen, Unoready Pen, and prefilled syringe. If appropriate, your provider can train you or your caregiver to give Cosentyx (secukinumab) injections at home. Refer to the instructions for use, depending on the product you have for how to properly inject the medication.
When you're ready for yourCosentyx (secukinumab) dose, take the medication out of the carton and lay it on a flat surface to warm up. This should take about 15 to 30 minutes (for the Sensoready Pen and 75 mg and 150 mg prefilled syringes) or 30 to 45 minutes (for the Unoready Pen and 300 mg prefilled syringe). Don't try to warm up the medication any other way (e.g., microwave or run under hot water) because this can damage it. Don't freeze or shake the medication either.
Always check that the medication is clear, colorless or slightly yellow, and doesn't have particles. If Cosentyx (secukinumab) is discolored, cloudy, or has particles, don't use it. Contact your pharmacy about a replacement.
You can self-inject into the front of your thighs or stomach at least 2 inches away from your belly button). If someone else is giving you the injection, they can inject Cosentyx (secukinumab) into the outside of your upper arms.
Don't inject Cosentyx (secukinumab) into skin that is tender, bruised, red, hard, or in an area affected by psoriasis. Rotate the site of injection with each administration to avoid any irritation. Never inject it into your muscle or vein.
After your Cosentyx (secukinumab) injection, place the medication in a sharps container or a heavy-duty plastic container (e.g., empty milk carton, laundry detergent bottle) to lower the risk of needle-stick injuries. Don't throw away syringes or autoinjectors into your trash can. Visit the FDA's website for guidance on how to safely throw away your sharps container in your specific state.
Cosentyx (secukinumab) can cause some serious health issues. This risk may be even higher for certain groups. If this worries you, talk to your doctor or pharmacist about other options.
Risk factors: Active, chronic, or recurrent infection | Having other conditions that raise your risk of infection
Cosentyx (secukinumab) can make it more difficult for your body to fight off germs. This raises your risk for bacterial, viral, or fungal infections that are harder to treat. Let your provider know if you feel sick during treatment. If you have an infection, they might ask you to stop taking Cosentyx (secukinumab) so your body can fight it off. Contact your provider if you develop symptoms of an infection, such as fever, cough, chills, and body aches.
Cosentyx (secukinumab) can also cause new or old tuberculosis (TB) infections to come back. You'll need to get tested for TB before you start this medication and get treated if it's confirmed that you have TB. Tell your provider about your medical conditions and medications to make sure Cosentyx (secukinumab) is safe to take.
It's best to be up-to-date on all your vaccines before you start Cosentyx (secukinumab). Avoid getting live vaccines during treatment because it's not known whether they're safe to get while you're taking Cosentyx (secukinumab). Examples of live vaccines include Varivax (chickenpox vaccine) and MMR (measles, mumps, and rubella vaccine). Let your provider or pharmacist know that you're taking Cosentyx (secukinumab) before you get any vaccines.
Risk factors: Allergy to latex (for Sensoready Pen and prefilled syringes)
It's possible to have a serious allergic reaction to Cosentyx (secukinumab). These allergic reactions can include difficulty breathing; hives; swelling of your face, lips, tongue, or throat; or any other symptom of anaphylaxis.
Tell your provider if you're allergic to latex because the cap on the prefilled syringe and Sensoready Pen contains latex. Get medical help right away if you have an allergic reaction to Cosentyx (secukinumab) at any time during treatment.
There have also been reports of eczema-like skin problems from Cosentyx (secukinumab). People who reported this had it happen days to months after the first dose of Cosentyx (secukinumab). Contact your provider if you notice changes in your skin (rash, hives, itchiness, redness, swelling).
In clinical studies, some people with inflammatory bowel disease (IBD) experienced worsening symptoms or IBD flare-ups while taking Cosentyx (secukinumab). Before starting, let your provider know if you have a history of IBD. Contact your provider if you have stomach pain, bloody stools, diarrhea or constipation that doesn't get better, or sudden weight loss while taking Cosentyx (secukinumab).
Adults
Plaque psoriasis (PsO) and hidradenitis suppurativa: The typical starting dose is 300 mg injected under the skin weekly for 5 weeks. After that, the maintenance dose is usually 300 mg injected monthly.
Psoriatic arthritis (PsA), ankylosing spondylitis (AS), and non-radiographic axial spondyloarthritis (nr-axSpA): The starting dose can be optional; if given, the typical dose is 150 mg injected under the skin (SQ) weekly for 5 weeks. After that, the maintenance dose is usually 150 mg injected under the skin monthly. If appropriate, your provider might raise your dose to 300 mg monthly.
Children
Cosentyx is approved for children to treat PsO (ages 6 years and older), PsA (ages 2 years and older), and enthesitis-related arthritis (ages 4 years and older).
Body weight 33 lbs to 110 lbs: The typical starting dose is 75 mg injected under the skin weekly for 5 weeks. After that, the maintenance dose is usually 75 mg injected monthly.
Body weight 110 lbs or more: The typical starting dose is 150 mg injected under the skin weekly for 5 weeks. After that, the maintenance dose is usually 150 mg injected monthly.
Cosentyx (secukinumab) can also be given as an injection through the veins for PsA, AS, and nr-axSpA for adults only. Your provider will calculate the dose based on your body weight. The injection is usually given by a healthcare provider in a clinic setting.
Plaque psoriasis (PsO) in people ages 6 years and older
Psoriatic arthritis (PsA) in people ages 2 years and older who weigh at least 33 lbs
Ankylosing spondylitis (AS) in adults
Non-radiographic axial spondyloarthritis (nr-axSpA) in adults
Enthesitis-related arthritis in people ages 4 years and older who weigh at least 33 lbs
Hidradenitis suppurativa in adults
Active psoriatic arthritis
Plaque psoriasis
Mouth sores from Behçet’s disease
Moderate-to-severe plaque psoriasis in people ages 6 years and older
Psoriatic arthritis (PsA) in adults
Ankylosing spondylitis (AS) in adults
Non-radiographic axial spondyloarthritis (nr-axSpA) in adults
By signing up, I agree to GoodRx's Terms and Privacy Policy, and to receive marketing messages from GoodRx.
Beringer, A., et al. (2019). Systemic effects of IL-17 in inflammatory arthritis. Nature Reviews Rheumatology.
Drugs and Lactation Database (LactMed®). (2023). Secukinumab. National Institute of Child Health and Human Development.
McInnes, I. B., et al. (2017). Secukinumab sustains improvement in signs and symptoms of psoriatic arthritis: 2 year results from the phase 3 FUTURE 2 study. Rheumatology.
Menter, A., et al. (2016). Efficacy of secukinumab on moderate-to-severe plaque psoriasis affecting different body regions: A pooled analysis of four phase 3 studies. Dermatology and Therapy.
Novartis Pharmaceuticals Corporation. (n.d.). Using your prefilled syringe.
Novartis Pharmaceuticals Corporation. (n.d.). Watch how to inject using the Sensoready Pen.
Novartis Pharmaceuticals Corporation. (n.d.). Watch the UnoReady Pen Injection training video (300 mg).
Novartis Pharmaceuticals Corporation. (2023). Cosentyx- secukinumab injection; secukinumab injection, solution, concentrate [package insert]. DailyMed.
Țiburcă, L., et al. (2022). The treatment with interleukin 17 inhibitors and immune-mediated inflammatory diseases. Current Issues in Molecular Biology.
U.S. Food and Drug Administration. (2021). Safely using sharps (needles and syringes) at home, at work and on travel.
Weiss, P. F. (2012). Diagnosis and treatment of enthesitis-related arthritis. Adolescent Health, Medicine and Therapeutics.
Zenobia, C., et al. (2015). Basic biology and role of interleukin-17 in immunity and inflammation. Periodontology 2000.
Research prescriptions and over-the-counter medications from A to Z, compare drug prices, and start saving.